In patients with resected local kidney cancer at high risk for recurrence, adjuvant therapy with sorafenib or sunitinib did not increase survival in a double-blind, placebo-controlled Phase III trial (Lancet 2016 Mar 8. [Epub ahead of print], PMID: 26969090).
Moreover, treatment with sorafenib (Nexavar, Bayer/Onyx) or sunitinib (Sutent, Pfizer) was associated with substantial toxicity, which led to treatment discontinuation despite reductions in drug dose.
Investigators led by Naomi B. Haas,